NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine

Inclusion Criteria:

Patients will be eligible for enrollment if they fulfill all of the following criteria:

1. Histologically proven tumor type known to express NY-ESO-1 or LAGE-1 (prostate cancer, breast cancer, bladder cancer, hepatocellular cancer, synovial sarcoma, leiomyosarcoma, head and neck, lung cancer, esophageal, ovarian, neuroblastoma); or NY-ESO-1 or LAGE-1 positive tumors determined by reverse transcriptase and polymerase chain reaction (RT-PCR) analysis, preferably, or immunohistochemistry or expression of LAGE-1 by RT-PCR.
2. Advanced disease and have declined, delayed, failed or completed standard therapy.
3. Full recovery from surgery.
4. Expected survival of at least 6 months.
5. Karnofsky performance scale >60.
6. Adequate bone marrow, kidney, liver and immune functions.

Exclusion Criteria:

1. Clinically significant heart disease (NYHA Class III or IV).
2. Other serious illnesses, e.g., serious infections requiring antibiotics or bleeding disorders, clinically significant liver or renal insufficiency requiring treatment.
3. Patients with serious intercurrent illness, requiring hospitalization.
4. Known HIV, Hepatitis B or Hepatitis C positivity.
5. History of autoimmune diseases (e.g. SLE, scleroderma). Vitiligo is not an exclusion criterion.
6. Concomitant systemic treatment with corticosteroids, anti-histaminic drugs or non-steroidal anti-inflammatory drugs. Specific COX-2 inhibitors are permitted. Low dose aspirin is permitted. Topical or inhalational steroids are permitted.
7. Evidence of skin disease (e.g. psoriasis, eczema or keloid formation) at the proposed administration site.
8. Allergy to gold (including gold jewelry).
9. History or evidence of chrysotherapy (gold salts).
10. Chemotherapy, radiation therapy, or immunotherapy within 4 weeks prior to first dosing (6 weeks for nitrosoureas).
11. Other malignancy within 3 years prior to entry into the study, except for treated non-melanoma skin cancer, cervical carcinoma in situ and incidental prostate cancer on radical cystoprostatectomy specimen.
12. Mental impairment, in the opinion of the investigator, may compromise the ability to give informed consent and comply with the requirements of the study.
13. Lack of availability for immunological and clinical follow-up assessments.
14. Participation in any other clinical trial involving another investigational agent within 4 weeks prior to first dosing.
15. Pregnancy or breastfeeding.
16. Women of childbearing potential: Refusal or inability to use effective means of contraception.